ACI
GHDX

AMP Capital Investors’s Genomic Health, Inc. GHDX Stock Holding History

AMP Capital Investors’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,966
Closed -$253K – 1226
2018
Q4 		$253K Buy
+3,966
New +$278K ﹤0.01% 1065

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AMP Capital Investors's GHDX Position: Q1 2019 in Review

AMP Capital Investors sold out of Genomic Health, Inc. (GHDX) in Q1 2019, closing a stake of 3,966 shares — an estimated $253K sold.

AMP Capital Investors first reported a position in GHDX in Q4 2018 and held it in 1 quarter. The position peaked at $253K in Q4 2018. 267 funds tracked by Wall St. Rank hold GHDX as of Q1 2019.

  • AMP Capital Investors reported no remaining Genomic Health, Inc. position as of Q1 2019 after selling out during the quarter.
  • AMP Capital Investors sold 3,966 Genomic Health, Inc. shares in Q1 2019, an estimated $253K.
  • AMP Capital Investors first reported a position in Genomic Health, Inc. in Q4 2018 and held it in 1 quarter.
  • AMP Capital Investors's Genomic Health, Inc. position peaked at $253K in Q4 2018.
  • 267 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2019.

Based on AMP Capital Investors's 13F filing for Q1 2019, filed 15 May 2019.